Drug name - Reclast

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8052987 NOVARTIS Method of administering bisphosphonates Oct, 2023

(1 year, 27 days from now)

US7932241 NOVARTIS Pharmaceutical products comprising bisphosphonates Feb, 2028

(5 years from now)

US7932241

(Pediatric)

NOVARTIS Pharmaceutical products comprising bisphosphonates Aug, 2028

(5 years from now)

Drugs and Companies using ZOLEDRONIC ACID ingredient

Treatment: Treatment and prevention of postmenopausal or glucocorticoid-induced osteoporosis and treatment to increase bone mass in men with osteoporosis

Dosage: INJECTABLE;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 5MG BASE/100ML INJECTABLE;INTRAVENOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.